| abstract |
A nasal vaccine capable of inducing an effective immune response in the nasal cavity is provided. Specifically, a compound having NKT cell activation action, particularly the compound of formula (I) [Wherein, R represents an aldopyranose residue, and X ′ represents an oxygen atom, a sulfur atom or —NH—. M represents an integer of 0 to 26, n represents an integer of 0 to 16, and p represents an integer of 0 to 4. Me represents a methyl group. ], Or formula (II) A compound such as (2S, 3S, 4R) -1- (α-D-galactopyranosyloxy) -2-hexacosanoylamino-3,4-octadecanediol represented by And a nasal vaccine containing an effective amount of the immunogen. |